Concepedia

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

Richard Haubrich, Dan Berger, Philippe Chiliade, Amy E. Colson, Marcus A. Conant, Joel E. Gallant, Timothy Wilkin, Jeffrey P. Nadler, Gerald Pierone, Michael S. Saag,

AIDS · 2007 · 113 citations · 9 references

DOI

Abstract

TMC114/r treatment resulted in greater virological and immunological responses in ART-experienced patients compared with CPI at 24 weeks.

References

9

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A 3-Year Randomized Trial</SUBTITLE>

Joel E. Gallant · JAMA · 2004 · 1.3K citations

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Jacob Lalezari, Keith Henry, Mary O’Hearn et al. · New England Journal of Medicine · 2003 · 909 citations · Full text

TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates

Sandra De Meyer, Hilde Azijn, Dominique Surleraux et al. · Antimicrobial Agents and Chemotherapy · 2005 · 354 citations · Full text

, , +15

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

Victor DeGruttola, Lynn P. Dix, Richard T. D’Aquila et al. · Antiviral Therapy · 2000 · 330 citations · Full text

, , +19

Drug Resistance Mutations in HIV-1.

PubMed · 2003 · 282 citations

, , +19